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Risk factors and primary prevention 
of lung cancer. Cessation of cigarette 
addiction 
ABSTRACT
Despite the huge knowledge about the risk factors associated with lung cancer, this disease remains the leading 
cause of cancer deaths in highly developed countries. The reason for this phenomenon is the increasing pol-
lution of the natural environment and, above all, the difficulties in eliminating the addiction to smoking. In large 
Polish urban agglomerations, the exposure to particulate matter containing hydrocarbons on its surface, to free 
hydrocarbons, nitrogen and sulphur oxides is constantly increasing. Moreover, almost 25% of the Polish population 
smoke cigarettes and the elimination of smoking addiction through psychotherapy, nicotine replacement therapy 
and pharmacotherapy are sometimes ineffective. This article presents that the use of tobacco-burning products 
other than cigarettes (e.g., cigars or pipes) and products containing marijuana are as dangerous to health as 
classical cigarettes. Other nicotine-containing products have also appeared: e-cigarettes and tobacco heating 
systems. These products are highly addictive to nicotine, but the aerosols, that are produced by them, contain fewer 
toxic substances than cigarette smoke. Therefore, there are reasons to use these products instead of traditional 
cigarettes in people who are highly addicted to nicotine (after exhaustion of other treatment options) to reduce 
health risks, including lung cancer risk. However, it must be evoked that only a complete smoking cessation and 
the use of nicotine-containing products could be effective in reducing the risk of lung cancer.
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Introduction
Lung cancer is the second most common cancer 
among men and women. According to the National 
Cancer Register (NCR), in 2018 lung cancer ac-
counted for 16.1% of diagnosed cancer cases in men 
(after prostate cancer, which accounted for 19.6% of 
cancer cases in men) and 9.3% of diagnosed cancer 
cases in women (after cancer breast, which accounted 
for 22.5% of cancers in women). The NCR estimated 
that in 2020 there were 22,539 cases of lung cancer in 
Poland (13,553 in men and 8,986 in women). On the 
other hand, Globocan, operating under the patronage 
of the International Agency for Research on Cancer 
(IARC) and WHO (World Health Organization), esti-
mated the number of new lung cancer cases in Poland 
in 2020 at 29,509 (18,277 men and 11,232 women). 
Lung cancer remains the leading cause of death from 
malignant cancers in highly developed countries. 28.2% 
of men and 17.5% of women with cancer die from lung 
cancer. According to Globocan, the number of deaths 
from lung cancer in Poland in 2020 was 27,444 patients. 
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For comparison, the second most common cause 
of death in cancer patients was colorectal cancer 
— 9,382 Poles died of colorectal cancer. The reasons 
for such a high number of deaths from lung cancer are 
the high incidence of this cancer due to the high expo-
sure of a quarter of our population to tobacco smoke 
carcinogens and the still very poor prognosis (less than 
20% of patients survive 5 years after diagnosis) [1, 2].
As can be concluded from the above data, it is 
necessary to conduct intensive lung cancer prevention 
programs. One of them should be primary prevention 
aimed at eliminating the addiction to smoking and 
exposure to other carcinogens. As part of secondary 
prevention, the use of low dose computed tomography 
should be developed to detect early asymptomatic cases 
of lung cancer in a group at high risk of developing 
this disease (tobacco smokers). The development of 
new, personalized therapy methods (immunotherapy, 
molecularly targeted therapies) is also important, as 
they increase the chance to cure patients after radical 
treatment (surgery, chemoradiotherapy) and signifi-
cantly extend the life of patients with advanced cancer 
(even by over 5 years).
Environmental and occupational factors
The International Agency for Research on Cancer 
(IARC) recognizes outdoor air pollution as a risk factor 
for lung cancer. Air pollution data show that lung cancer 
incidence increases by 30–50% in areas with high levels 
of ambient air pollution compared to areas with lower 
levels of ambient air pollution [3, 4].
Particulate matter (PM) can damage various organs 
and cause many diseases. PM is classified according to 
particle size. PM10 (particles ≤ 10 µm in diameter), 
PM2.5 (particles ≤ 2.5 µm in diameter) also called fine 
particles and PM0.1 (particles ≤ 0.1 µm in diameter) 
also called ultrafine particles. Exposure to these parti-
cles has various health effects, which are partly due to 
how these particles travel in the lower respiratory tract 
and how they affect the lung defence mechanisms [5]. 
The health risks of PM0.1 are very high, but their exact 
role in many diseases is still unclear. Their high produc-
tion and rapid redistribution make accidental exposure 
common in the general population. Many studies have 
shown that the smaller the size of the particles, the 
greater their mutagenic potential. The most important 
carcinogen was considered to be the total surface area 
of  the retained particles, although the dose, particle 
type and exposure time were also important. The size 
of the particles depends largely on the size of the inter-
nal carbon core on which hydrocarbons and sulphate 
compounds responsible for the carcinogenesis process 
are absorbed [6, 7].
A positive correlation has also been observed be-
tween various indicators of indoor air pollution and the 
risk of lung cancer. Indoor air pollution is believed to be 
a risk factor for lung cancer, especially among female 
non-smokers and in less developed countries. Indoor 
air pollution is associated with coal combustion in 
poorly ventilated homes, combustion of wood and other 
solid fuels (biomass combustion), and the production of 
fumes from high-temperature cooking with unrefined 
vegetable oils. In addition, in airtight rooms in houses 
built mainly in volcanic areas, radon may accumulate 
from soil and water. Radon is a radioactive noble gas 
responsible for the greatest exposure of humans to 
natural ionizing radiation. It is believed that in some 
areas, inhalation of radon may be the second cause of 
lung cancer after smoking [8].
Exposure to several occupational factors carries with 
it consequences in the form of the development of lung 
diseases, including lung cancer. The most important 
occupational carcinogens include asbestos, silica, heavy 
metals, and polycyclic aromatic hydrocarbons [9, 10]. 
All forms of asbestos (chrysotile and amphibole, in-
cluding crocidolite, amosite and tremolite) are carci-
nogenic, although chrysotile is less potent than other 
types, possibly because it is more efficiently cleared 
from the lungs. In many underdeveloped countries, 
occupational exposure to asbestos remains widespread 
[11, 12]. Chromium [VI] compounds increase the risk 
of lung cancer in people employed in the production of 
chromates, chromate pigments, chrome plating and fer-
rochrome plating. There was no such risk among work-
ers exposed exclusively to chromium compounds [III]. 
Workers exposed to nickel salts and workers involved in 
the production of cadmium batteries using copper and 
cadmium alloys also have an increased risk of lung cancer. 
High exposure to inorganic arsenic occurs mainly among 
workers employed in the steel industry. An increased 
risk of lung cancer has also been reported among people 
exposed to high levels of arsenic in drinking water [13]. 
Other groups with an increased risk of exposure to arsenic 
are fur handlers (tanners), producers, people employed in 
the production of sheep fur and pesticide cleaning (bath) 
mixtures, and vineyard workers [14]. An increased risk of 
lung cancer has also been reported among patients with 
silicosis. Many studies have looked at workers exposed 
to crystalline silica in foundries, pottery, ceramics, diato-
maceous earth mining, brickworks and stone cutting [15].
Polycyclic aromatic hydrocarbons are a complex 
and important group of chemicals formed during the 
combustion of organic material. An increased risk of 
lung cancer has been reported in several industries 
and occupations related to exposure to PAHs, such as 
aluminium production, coal gasification, coke produc-
tion, iron and steel foundry, tar distillation, roofing, and 
chimney cleaning. An increased risk of lung cancer has 
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also been suggested for those employed in several other 
industries, including shale oil extraction, wood impreg-
nation, roofing, and carbon electrode production [16].
Vehicle exhaust and other internal combustion 
engines constitute an important group of PAH mix-
tures as they contribute significantly to air pollution. 
Occupational exposure to exhaust fumes from diesel 
engines is common and the issue of its carcinogenicity 
has been the subject of many epidemiological studies in 
recent years. While the results are contradictory, many 
assessments seem to confirm that high occupational 
exposure to diesel exhaust over an extended period 
may be associated with an increased risk of lung cancer.
The SYNERGY project collected information on 
occupation and smoking in 13,304 lung cancer patients 
and 16,282 healthy people from 11 studies conducted in 
Europe and Canada. Exposure to diesel was associated 
with an increased risk of lung cancer with an Odds Ratio 
(OD) of 1.31 (p < 0.01) and depended on the exposure 
time and exhaust dose [17, 18]. Dai et al. [19] studied the 
relationship between exposure to exhaust fumes from 
diesel engines and the inflammatory response of the 
body. There was a significant decrease in blood levels 
of MIP-1b and IL-8 in people exposed to exhaust gases 
compared to the control group. Lower levels of these 
markers were also observed with increasing exposure to 
PM2.5. IL-8, MIP-1b are chemokines that play an impor-
tant role in the recruitment of immunocompetent cells 
for immune defence and removal of cancer cells [19].
Air pollution is a silent epidemic. However, it is 
a threat that can be minimized with appropriate ac-
tions. Eliminating or at least reducing air pollution will 
result in an improvement in the health of the entire 
population. Prevention of lung cancer in this respect 
should include the control of occupational exposure, as 
well as indoor and outdoor air pollution [20, 21].
Smoking tobacco and other substances
Smoking is the cause of 90% of lung cancer in men 
and 80% in women. Smokers are thirty times more likely 
to die from lung cancer than non-smokers. Cigarette 
smoke contains over 7,000 chemical compounds, includ-
ing over 70 compounds recognized as carcinogenic [22]. 
These compounds are formed during the combustion 
of tobacco at the end of a cigarette, which takes place 
at a temperature of over 750°C, and during pyrolysis, 
which takes place slightly deeper at the temperature of 
300–700°C. In addition, the process of tobacco combus-
tion at the end of a cigarette heats the air which is sucked 
by the smoker through the rest of the cigarette. Due to 
its high temperature, the air passing through the ciga-
rette evaporates nicotine and other volatile substances 
contained in the cigarette. This mixture goes as far as to 
the alveoli and is then absorbed into the smoker’s blood-
stream. It contains 93 toxic compounds [Harmful or 
Potentially Harmful Constituents (HPHCs)] described 
by the Food and Drug Administration (FDA) in 2012, 
causing the five most serious health consequences of 
smoking (cancer, cardiovascular diseases, respiratory 
diseases, reproductive function disorders, addiction). 
Tobacco-dependent cancers, apart from lung cancer, in-
clude cancer of the larynx, throat, oesophagus, stomach, 
mouth, kidneys, bladder, and pancreas. Chronic obstruc-
tive pulmonary disease is one of the leading causes of 
premature death in cigarette smokers. Cardiovascular 
diseases caused by cigarette smoking include ischemic 
heart disease, lower limb vessel disease, cerebrovascular 
disease, and arterial hypertension. The number of years 
of life lost and disability among smokers compared to 
non-smokers is 10. Giving up smoking reduces the risk 
of serious diseases, but the risk of lung cancer is halved 
only 10 years after giving up smoking [23, 24].
The most dangerous substances found in very high 
concentrations in tobacco smoke include benzo(a)pyr-
ene, nitrosamine, naphthalene, pyrene, naphthylamine, 
methanol, acetone, hydrogen cyanide, toluidine, am-
monia, urethane, arsenic, cadmium, polonium, phenol, 
butane, vinyl chloride, dibenzo acridine, toluene, carbon 
monoxide. A highly addictive substance is nicotine, 
which has not been proven to be carcinogenic, although 
its metabolites have been established to be highly 
carcinogenic (this will be described in the chapter on 
e-cigarettes). The main carcinogenic factors of tobacco 
smoke are polycyclic aromatic hydrocarbons and volatile 
N-nitrosamines, which are converted in the body into 
metabolites of equally high toxicity [25, 26].
Epidemiological evidence of the harmfulness of ciga-
rette smoking began to appear in the 1950s and concerned 
the association of cigarette smoking with the occurrence 
of lung cancer and cardiovascular diseases [27]. In 1964, 
the results of retrospective and prospective studies were 
announced in the United States which proved a 5- to 
20-fold increase in the risk of lung cancer in smokers [28]. 
Since cigarette smoking has been linked to lung cancer and 
other diseases, the tobacco industry has started to reduce 
the content of harmful substances in their products. Filters 
were gradually added, they were modified with perfora-
tions (small spaces to dilute the smoke), tobacco was 
reconstructed, and the quality of paper and additives was 
improved. These effects reduced the content of nicotine 
and tar in cigarette smoke, which, however, remained one 
of the main causes of civilization diseases.
Comparing the effects of smoking cigarettes with 
smoking cigars and pipes is quite difficult. The design 
of the products and the different methods of their 
use, resulting in a different exposure to smoke, play 
a significant role here. Size aside, the main difference 
in the structure of cigars and cigarettes is the lack of 
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a filter. In cigarettes, the wrapping material for tobacco 
is paper and for cigars it is a tobacco leaf, increasing the 
final amount of nicotine and toxic substances released. 
For comparison, smoking one cigar provides from 
100 to 200 mg of nicotine, and one cigarette provides an 
average of 8 mg. This means that the smoke from one 
cigar contains at least the same amount of nicotine as 
there is in one packet of unfiltered cigarettes. However, 
because cigars are consumed differently, the smoke 
usually remains in the mouth, rather than being inhaled 
into the lungs, as is the case with cigarettes. Similar de-
pendencies as in the case of smoking cigars also occur 
in the users of pipes and water pipes. It should be noted 
that volatile substances are much better absorbed from 
the lungs than through mouth tissues, which explains 
the higher concentration of harmful substances in the 
blood of cigarette smokers compared to cigar and pipe 
smokers. At the same time, oropharyngeal cancer is 
much more common in cigar smokers than in traditional 
cigarette smokers [29–32].
All highly developed countries have legislation to 
eliminate smoking in society. In Poland, the Act of 
November 9, 1995, on health protection against the 
consequences of using tobacco and tobacco products is 
in force (Journal of Laws of 2015, items 298 and 1916, 
and of 2016, item 960). This act was updated on July 22, 
2016. Many countries have adopted an endgame strategy 
to either eliminate tobacco from society completely 
or to reduce the proportion of smokers to 5% of the 
population. The first group included Sweden, Ireland 
and New Zealand (until 2025), Denmark and Finland 
(until 2030), and Canada and Scotland (until 2035). 
The second group includes Great Britain and France. 
Poland is set to become a tobacco-free country by 2030.
The carcinogenic effects of the substances generated 
during the combustion of cannabis have been studied 
very poorly. Depending on the species, cannabis contains 
over 420 chemicals, 61 of which are cannabinoids. More 
than 2,000 compounds are formed by pyrolysis when 
smoking cannabis and are represented by different 
classes of chemicals including nitrogen compounds, 
amino acids, hydrocarbons, terpenes, and simple 
fatty acids. Cannabis smoke also contains carcinogenic 
polycyclic aromatic hydrocarbons as well as other toxic 
products of combustion. They are similar to tobacco 
smoke, but the way cannabis is smoked results in higher 
exposure to smoke. However, the relationship between 
chronic obstructive pulmonary disease and cannabis 
smoking has not been fully proven, although chronic 
bronchitis (coughing, dyspnoea, and sputum production) 
is often observed in cannabis smokers. The impact of 
cannabis smoking on lung cancer risk was investigated 
in a group of 49,321 men aged 18–20 years during con-
scription in Sweden in 1969–1970. Participants in this 
study were followed up until 2009 in national medical 
registries for lung cancer. Analyses showed that heavy 
cannabis smoking was significantly associated with 
more than a twofold increase in the risk of lung cancer 
[OR = 2.12, 95% confidence interval (CI): 1.08–4.14] 
over the 40-year follow-up period [33–35].
Electronic cigarettes
E-cigarettes constitute a diverse group of rechargeable 
electronic nicotine inhalers with several thousand mod-
els. The device causes the inhalation liquid in the evapo-
rator to change under the influence of high temperature 
(150–250°C) into an aerosol inhaled by the user (instead of 
the smoke inhaled when smoking cigarettes). The inhala-
tion liquid usually consists of propylene glycol, glycerine, 
flavours, and nicotine in various concentrations (from 0 to 
36 mg/mL). In the past, evaporators were disposable. Now, 
there are also models with liquid in the evaporator that can 
be refilled when the content of the refill container finishes. 
Due to the generally low nicotine content of e-cigarettes, 
e-cigarette users tend to use e-cigarettes frequently. 
Moreover, the use of e-cigarettes has become fashion-
able among adolescents, which may lead to nicotine 
addiction and then to the use of traditional cigarettes 
later in life. It is estimated that up to 5% of primary 
school students and over 20% of high school students 
have regular contact with e-cigarettes. In addition, us-
ing e-liquids after purchasing an expensive device is 
cheaper than buying cigarettes. That is why legal regula-
tions have been created to limit access to e-cigarettes. 
The pulmonary toxicity of e-cigarettes and their influ-
ence on cancer incidence that is discussed with increas-
ing frequency is also important [36].
In art. 20 of the Directive of the European Parlia-
ment and of the Council of the European Union (EU) 
of April 3, 2014, on tobacco products (2014/40/EU), 
there are provisions for electronic cigarettes sold in 
the EU. The directive specifies the maximum con-
centration of nicotine in vaporizers and removable 
containers and requires the composition of the liquid 
used in e-cigarettes to be specified, including the exact 
concentration of nicotine. According to the directive, 
e-cigarettes should be childproof and easy to handle 
and have a refilling mechanism that allows leak-free 
refilling. The ingredients of e-cigarettes must be of high 
purity, and e-cigarettes should provide a standardized 
amount of nicotine. Health warnings for e-cigarettes 
informing consumers that they contain nicotine and 
should not be used by non-smokers are mandatory in 
EU countries. The e-cigarette leaflet should contain 
information about side effects that must be reported 
and about addictive properties. In EU countries there is 
a ban on e-cigarette advertising [37]. "Public Health Eng-
land" found that the use of standardized and certified 
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electronic cigarettes is 95% less harmful than smoking 
traditional cigarettes [38, 39].
In August 2016, the WHO recommended a ban on 
the use of e-cigarettes indoors or where smoking is pro-
hibited [40]. This is because non-users of these products 
may be exposed to chemicals and e-cigarette aerosols.
In many EU countries, specific regulations are regu-
lating the e-cigarette market. Unfortunately, in Poland, 
the approval of e-cigarettes for sale is insufficiently 
controlled by the Bureau for Chemical Substances 
established in the regulation of the Minister of Health 
of November 9, 2015 (Journal of Laws of 2015, item 
1953). E-cigarettes are admitted to trading in Poland 
based on a notification, i.e., a notification by the manu-
facturer. Therefore, the composition of e-liquids is not 
controlled in any way. This creates a potential risk of 
interference with the composition of the liquid (so-called 
premixes). According to Polish legislation, an e-cigarette 
is not a tobacco product. The nicotine-containing liquid 
contained in the refill container must not exceed 10 mL 
or, in the case of single-use containers, 2 mL. The nico-
tine content in the liquid must not exceed 20 mg/mL. 
The liquid must not contain vitamins or other additives 
that give the impression that a tobacco product is ben-
eficial to health, caffeine or taurine, or other additives 
and stimulants associated with energy and vitality (e.g. 
legal highs) and additives that in an unburned form have 
carcinogenic, mutagenic or reprotoxic properties. De-
spite these limitations, there are several hundred types 
of e-liquids and e-cigarettes available in Poland without 
proper authorization of the e-liquid composition [41].
Unlike Polish legislation, since August 8, 2016, 
the FDA ordered e-cigarettes to be subject to tobacco 
product regulations. As in the EU, in the USA there is 
a ban on selling e-cigarettes to minors. The FDA has 
classified e-cigarettes as stimulant delivery devices and 
they are therefore regulated under the Federal Food, 
Drug and Cosmetic Act (FDCA). After the detection 
of serious respiratory diseases related to the inhalation 
of untested substances from e-cigarettes, which resulted 
in the death of six people in the USA, in September 
2019 the US government began working on introducing 
a complete ban on e-cigarettes [42].
In April 2019, there were reports of severe respira-
tory failure due to lung damage in e-cigarette users in 
the United States. There were more patients with this 
syndrome in Great Britain and Japan [43, 44]. By Janu-
ary 21, 2020, a total of 2,711 hospitalized patients and 
60 deaths due to respiratory failure after the use of 
e-cigarettes were reported to the Centres of Disease 
Control and Prevention (CDC) [15]. Most of the cases 
concerned young people. 80% of patients reported 
the use of tetrahydrocannabinol (THC) in e-liquids, 
approximately 55% of patients reported THC added 
to nicotine-containing products, and 13% of patients 
reported exclusive use of nicotine-containing prod-
ucts. Symptoms of respiratory failure developed within 
days to weeks of exposure. THC is an organic chemical 
compound of the cannabinoid group and is the main 
psychoactive substance found in the cannabis plant. 
The CDC and the FDA, as part of the investigation 
carried out in 2019 and 2020, confirmed the presence 
of THC in vaporization products. Most vaporization 
liquids also contained significant amounts of Vitamin 
E Acetate (tocopherol), which was used in street sales 
to dilute flavours and THC [45]. Previously, vitamin E 
was used in low concentrations in e-liquids (up to 20% 
of the volume of the cartridge or was prohibited). Due 
to the limited availability of illegal marijuana, as well 
as the high demand for this type of e-cigarette, illegal 
vendors used about 50% or more of diluents in e-liquids 
[45]. For these reasons, the use of e-cigarettes, especially 
from an uncertain source, should be considered risky.
Concerns about the carcinogenicity of e-cigarettes 
result from both inhalation of nicotine [46] and other 
chemicals that may be contained in the aerosols [42]. 
The interaction of nicotine with nicotinic acetylcholine 
receptors (nAChR) activates signalling pathways that 
trigger several responses such as increased cell pro-
liferation and survival. There is evidence from in vitro 
studies (breast, colorectal and lung cancer cell cultures) 
and in animal models (lung cancer) that nicotine may 
be carcinogenic and may accelerate tumour growth and 
promote metastasis [46]. In vitro studies have shown 
that nicotine increases cell proliferation, induces cell 
resistance to apoptosis, causes Epithelial-Mesenchymal 
Transition (EMT), which increases the migration and 
invasiveness of cancer cells and induces neoangiogenesis 
[47]. The pro-angiogenic effect of nicotine, resulting 
from the activation of endothelial cell proliferation 
and increasing the production of nitric oxide, which is 
a strong angiogenic factor, seems to be of the greatest 
importance for tumour progression. In high concentra-
tions, nicotine damages DNA and can induce necrosis of 
normal cells, but also the formation of new somatic mu-
tations and promotion of the carcinogenesis process with 
a decrease in the expression of suppressor genes such 
as CHEK2 (Checkpoint Kinase 2) [48]. Moreover, in in 
vitro cultures (lung cancer cell lines: H460 and A549), 
nicotine has been shown to reduce the antiproliferative 
and pro-apoptotic effects exerted by cytostatics and 
radiotherapy, which may result in a worse response to 
cancer treatment in patients who smoke or use other nic-
otine-containing products. This effect can be eliminated 
by the use of inhibitors of the alpha nAChR subunit, 
e.g., a-bungarotoxin. The products of nicotine metabo-
lism proved to be very carcinogenic in in vitro cultures 
and in animal models. These are N-nitrosonornicotine 
(NNN), responsible for the occurrence of stomach and 
oesophageal cancers, and nitrosamine ketone (NNK), 
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which is one of the most carcinogenic substances, as 
well as 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol 
(NNAL), which is a metabolite of the carcinogenic NNK 
in the lungs. All these substances have been found in 
the urine of people who smoke traditional cigarettes and 
use e-cigarettes. Nicotine may inhibit the anti-cancer im-
mune response by influencing the antigen presentation 
and activity of dendritic cells, increasing the production 
of pro-inflammatory cytokines, and intensifying oxida-
tive stress [48].
In addition, there is evidence that some substances 
found in e-cigarette fumes, such as formaldehyde and 
acrolein, certain flavour additives, vitamin E acetate, 
and even propylene glycol, can cause DNA damage 
and carcinogenesis, or be irritating to the respiratory 
tract, which may increase the risk of lung, mouth, and 
throat cancer. It is because e-liquids containing nico-
tine isolated from tobacco can contain contaminants 
such as nicotine oxides, cotinine, anabasine, anatabine, 
myosmine, acrolein and beta-nicotyrine, and even 
in small amounts toluene, and heavy metals such as 
cadmium, tin, nickel, and lead. Propylene glycol used 
in e-cigarettes can be contaminated with diethylene 
glycol and transform into propylene oxide. Some of 
these substances can form adducts with DNA, which 
leads to activating mutations in oncogenes (most often 
in the KRAS gene) and deactivating mutations in sup-
pressor genes (most often in the p53 and RB1 genes). 
However, it should be noted that compared to tradi-
tional cigarette smoke, the levels of toxic substances 
identified in e-cigarette aerosols were 10 to 450 times 
lower [48–55].
Despite the risk of carcinogenesis and respira-
tory damage associated with the use of e-cigarettes, 
a 2014 report by the Surgeon General of the United 
States concluded that there was insufficient evidence 
of carcinogenic effects of nicotine alone in vivo in 
humans. However, further studies were recommended 
to check whether exposure to the nicotine contained 
in, for example, e-cigarettes does not increase the risk 
of oropharyngeal, oesophageal, lung and pancreatic 
cancer [56]. Moreover, the health consequences of 
inhaling aerosol from e-cigarettes are unknown be-
cause no reliable safety study has been carried out on 
e-cigarette use due to the variety and a large number of 
manufacturers. The content of hazardous substances 
in e-liquids has not been thoroughly tested, nor has 
their permissible level been determined [57]. There-
fore, as early as in 2009, the FDA issued a warning 
that the use of e-cigarettes may pose a health risk [51]. 
In turn, the United Kingdom has introduced a proce-
dure under which medically tested e-cigarettes can 
be registered as medicinal products indicated for the 
reduction of abstinence syndrome in the treatment of 
nicotinism [58].
Heat-not-Burn systems
Heat-not-Burn (HnB) devices heat tobacco to 
200–350°C, releasing aerosols. The devices consist of 
a ceramic blade with electric wires connected to a battery 
with the possibility of charging from an external power 
source. The blade is located inside an acetate tube with 
a cellulose acetate mouthpiece. The polymer filter is de-
signed to cool the resulting aerosol. The compressed to-
bacco rod is made of a suspension of dried tobacco, 70% 
of which is tobacco, and humectants (water, glycerine, 
propylene glycol) to generate an aerosol. In comparison 
to e-cigarettes, tobacco heating systems are subject to 
more rigorous procedures of standardizing the content 
of various substances in the inhaled aerosol [59, 60].
Tobacco heating systems are not subject to the 
Directive of the European Parliament and the EU 
Council of April 3, 2014, on tobacco products, like 
e-cigarettes, because the first HnB products were cre-
ated in 2014. Therefore, there is no official position of 
EU agencies regarding HnB products. In November 
2020, a document aimed at assessing and introducing 
regulations on tobacco heating systems, as well as new 
regulations governing the approval of e-cigarettes for 
sale was subjected to social discussion [60].
Some EU countries have internal regulations for 
HnB products. The German Federal Institute for Risk 
Assessment and the Dutch National Institute for Public 
Health and the Environment have carried out appro-
priate tests, finding a reduction in the content of toxic 
substances in aerosols from HnB devices ranging from 
80% to 99% compared to cigarette smoke. However, it 
has been found that the use of heat-not-burn products 
is harmful to health, but most likely carries a signifi-
cantly lower risk of disease than smoking [61, 62]. Public 
Health England found that, compared to cigarettes, 
heat-not-burn products may present less exposure of 
users and bystanders to particulate matter and harmful 
and potentially harmful chemicals. In turn, the British 
Committee on Toxicity (COT) stated that although 
heat-not-burn products are still harmful to health, they 
are probably less dangerous than smoking traditional 
cigarettes [38, 39, 63].
In Poland, HnB products, like e-cigarettes, are sub-
ject to registration by the Chemical Substances Office. 
However, unlike electronic cigarettes, the market for 
heat-not-burn devices is better controlled. The proce-
dure for submitting heat-not-burn devices to the Office 
requires authorization (i.e., not only determining the 
aerosol composition, but also presenting test results 
for each new device), and not an only notification, as 
is the case with e-cigarette registration. Therefore, in 
December 2020, the Office stated that, like e-cigarettes, 
heat-not-burn products are often seen as an opportunity 
to give up smoking regular cigarettes. Declarations of 
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respondents affected by this situation may indicate that 
the effectiveness of heat-not-burn products in this re-
spect is much higher than that of e-cigarettes, although 
due to the small size of the studied groups, this data 
requires confirmation in further studies [41]. 
In October 2019, the FDA issued the first-ever deci-
sion to award a Modified Risk Order to eight tobacco 
products that do not burn or produce smoke. These 
products were based on the snus technology (cellulose 
bags containing powdered, moist tobacco, usually placed 
behind the upper lip). In turn, in July 2020, as part of 
the MRTP (Modified-Risk Tobacco Product) proce-
dure, after nearly 4 years of research analysis, the FDA 
decided to authorize the first tobacco heating system 
as a tobacco product that ensures lower exposure to 
harmful and potentially harmful substances compared 
to classic cigarettes. The registration process considered 
the state of scientific knowledge about these products, 
as well as the data of the manufacturer and independ-
ent researchers and the comments raised in the public 
debate [64, 65].
The content of harmful substances, including car-
cinogens, in tobacco heating systems, is usually com-
parable to the content of these compounds in certified 
and standardized e-cigarettes (however, as described 
in the previous chapter, not all e-liquids can be subject 
to such control). The nicotine content in HnB products 
is 0.5–1.3 mg per cartridge. The aerosol also contains 
glycerol, propylene glycol and water. Since the aerosol is 
made of real tobacco, when it is heated to a temperature 
of over 300°C, it may contain small amounts of toxic sub-
stances, such as compounds resulting from the chemical 
transformation of nicotine (similarly to e-cigarettes), ni-
trosamines, benzene, benzo(a)pyrene, 4-aminobiphenyl, 
acrolein, acetone, 2-butanone, methyl glycol, pyridine, 
hydroxyacetone, diacetyl, isopentane and numerous 
aldehydes (e.g. formaldehyde, acetaldehyde, propionic 
aldehyde, crotonic aldehyde, pentanal, benzaldehyde, 
heptanal, furfural). However, the content of toxic sub-
stances in the aerosol from HnB products is at the level 
of 8% to 3% of their content in the smoke of traditional 
cigarettes. The content of group 1 carcinogens from 
the IARC list in HnB aerosols is reduced compared to 
cigarette smoke by 97%, and of carcinogens identified 
by the FDA by 93%. The reduction of factors damaging 
the respiratory and cardiovascular systems and disrupting 
reproduction ranges from 92 to 94%. The levels of carbon 
monoxide, pyrene, acrylonitrile and aminophthalenes 
in aerosols from HnB products are reduced to almost 
zero, which is associated, among others, with a significant 
reduction in the content of carboxyhaemoglobin in the 
blood of people using HnB products compared to smok-
ers of traditional cigarettes [66].
Due to the short presence of HnB products on the 
market, no retrospective observations are determining 
the level of reduction in the incidence of tobacco-related 
cancers compared to smoking. Therefore, attempts were 
made to estimate the carcinogenicity of the aerosol of 
the HnB product based on detailed toxicological data. 
In a study published in Tobacco Control BMJ, the 
carcinogenic potency was defined as at least one order 
of magnitude lower than that of cigarette smoke [67]. 
Public institutions in some countries also performed 
their own detailed oncological risk assessment of the 
use of tobacco heating systems. In studies conducted 
by the Ministry of Health of Japan and the National 
Institute of Public Health in the Netherlands, the risk of 
cancer resulting from the use of HnB was estimated to 
be about 10 times lower compared to smoking, and the 
reduction of cumulative exposure to the main carcino-
gens of tobacco smoke was 10 to 25 times lower [68, 69]. 
The risk of cancer induction in the case of passive expo-
sure to HnB aerosols was estimated to be approximately 
3,000 times lower than that of cigarette smoke.
There are many in vitro, animal, and human stud-
ies that have compared the effects of substances in an 
aerosol produced when tobacco is heated and that of 
tobacco smoke. A team of researchers from the Institute 
of Experimental Biology of the Polish Academy of Sci-
ences showed a much greater effect of inhibiting oxygen 
consumption by the mitochondria of bronchial epithelial 
cells exposed to cigarette smoke in culture compared to 
an aerosol from the HnB device. Moreover, cigarette 
smoke had a much stronger effect on oxidative phospho-
rylation and expression of genes involved in the response 
to oxidative stress compared to an aerosol from the HnB 
device [70]. In a 6-month clinical trial Ludicke et al. [71] 
showed greater disorders of lipid metabolism (decrease 
in HDL cholesterol and increase in LDL cholesterol 
and triglycerides), increased inflammation (increase in 
the number of white blood cells, C-reactive protein and 
pro-inflammatory cytokines), impaired vascular endothe-
lial function, blood clotting, oxidative stress (increase in 
the concentration of 8-epiprostaglandin F2, 8-epi-PGF2), 
the level of carboxyhaemoglobin in smokers compared to 
people using HnB products. In people who switched from 
traditional cigarettes to HnB products, after 6 months of 
observation, the above-mentioned biochemical param-
eters and respiratory function improved, expressed by in-
creasing spirometric parameters, such as FEV1 (Forced 
Expiratory Volume in 1 second) [71].
Tobacco dependence therapy
Smoking tobacco causes a strong pharmacological 
addiction to nicotine and is at the same time the most 
important carcinogenic factor of lung cancer. When 
nicotine levels drop in blood, clinical withdrawal symp-
toms develop, forcing the smoker to continue smoking 
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and thus maintain adequate levels of nicotine in the 
blood. After a certain period of smoking, nicotine 
tolerance develops, which makes it necessary to take 
increasingly higher doses of nicotine to obtain the de-
sired effect. Tolerance arises by increasing the activity 
of nicotine metabolising enzymes and by increasing 
the number of nicotine receptors in the central nerv-
ous system. In addition to pharmacological addiction, 
smoking causes a behavioural addiction that consists 
of complex psychological, environmental, cultural, and 
social factors [72].
Non-pharmacological treatments for tobacco 
dependence consist of three components. The first is 
education on the harmful effects of tobacco smoking, 
conducted through specialist telephone consultations, 
educational brochures, radio, and television programs 
and on the Internet. The next stage is anti-smoking 
counselling conducted in a doctor’s office, among others, 
at a general practitioner and a specialist pulmonologist. 
The key to properly conduct anti-smoking counselling 
is a thorough interview, which can be used to assess 
the degree of nicotine addiction (including Schneider 
and Fagerström tests). The Fagerström questionnaire 
consists of 6 questions concerning the period from 
waking up to smoking the first cigarette, difficulties 
in refraining from smoking in forbidden places, the 
number of cigarettes smoked daily, the degree of dif-
ficulty in giving up the first cigarette, the time of the 
day when more cigarettes are smoked, smoking during 
a disease. The maximum number of points obtained 
in the Fagerström test is 10. The sum of points above 
6 indicates a strong degree of nicotine addiction and is 
an indication for replacement treatment when giving 
up smoking [72]. On this basis, the type of the most 
appropriate medical advice and the frequency of subse-
quent appointments can be planned. The third stage of 
addiction treatment is behavioural therapy, consisting 
of comprehensive medical and psychological counselling 
and short personal consultations, including learning to 
eliminate pro-tobacco stimuli as well as relaxation and 
motivational techniques [72].
The pharmacological treatment of nicotine addic-
tion includes nicotine replacement therapy (NRT), 
psychotropic drugs (bupropion) and nicotinic cholin-
ergic antagonists (varenicline and cytisine). The use of 
tobacco heating systems as a method of treating tobacco 
addiction is still debatable [72].
Nicotine replacement therapy (NRT), introduced 
in the late 1970s, supplies the addicted smoker with 
nicotine, which eliminates acute withdrawal symptoms 
and reduces the number of nicotinic receptors, making it 
easier to abstain from smoking. Before starting replace-
ment treatment, one should be ascertained whether they 
are dealing with pharmacological dependence based on 
the results of the Fagerström questionnaire [72].
Various forms of NRT are available: transdermal 
systems (patches), chewing gums, lozenges, sublingual 
tablets, aerosols, and oral inhalers. These products are 
available in Poland without a prescription.
Patches provide stable levels of nicotine in the blood, 
making it easier to stop smoking, but when using them, 
in the event of nicotine craving, it is necessary to use 
emergency oral products. The nicotine contained in 
a patch gradually penetrates the skin and subcutaneous 
tissue into the blood and the brain. Patches come in 
different doses (7, 14 and 21 mg of nicotine in 24-hour 
patches and 5, 10 and 15 mg in 16-hour patches). Patches 
are applied to dry and hairless skin, on the upper body 
(chest, back, arms). To reduce the risk of a local skin 
reaction, patients should change the application site. 
Nicotine patches are generally well tolerated, especially 
in those most addicted to nicotine. Full treatment usually 
lasts about 10 weeks, during which the nicotine dose is 
gradually reduced [72].
Oral nicotine replacement therapy delivers nicotine 
on demand. Nicotine is absorbed through the oral mu-
cosa, satisfying short-term nicotine cravings. Chewing 
gum with nicotine and nicotine lozenges are available 
in doses of 2 mg and 4 mg. They are usually used as an 
addition to patches. The acidic environment of the oral 
cavity reduces the absorption of nicotine, therefore gums 
and lozenges should be used at least 15 minutes after 
eating or drinking [72].
The nicotine inhaler delivers nicotine in an aerosol to 
the oral mucosa where it is absorbed. The inhaler is not 
an e-cigarette (the liquid is not heated and no aerosol 
imitating smoke is produced). The device consists of 
a plastic tube in which a replaceable cartridge containing 
nicotine, often enriched with menthol as a fragrance, 
is placed. Nicotine is released as air flows through the 
inhaler. The inhaler is used as a cigarette and is espe-
cially useful for smokers with a behavioural addiction. 
Inhaler cartridges usually contain 10 mg of nicotine and 
are sufficient for four 20-minute inhalations [72].
Oral aerosols allow for the fast delivery of nicotine 
to the central nervous system. A dose contains 1 mg of 
nicotine. Usually, 1 or 2 doses are used every 30 minutes 
to 1 hour. The maximum allowable dose is 2 admin-
istrations at the same time or 4 administrations per 
hour. The maximum daily dose is 64 administrations 
over 16 hours. A gradual reduction in the number of 
doses is recommended. The recommended duration of 
use of this form of NRT is 3 to 6 months. Side effects 
of inhaler use include hiccups, headache, nausea, and 
throat irritation [72].
The results of a Cochrane systematic review of a me-
ta-analysis of 133 randomized trials of 64,640 smokers 
smoking at least 15 cigarettes a day indicate a significant-
ly greater likelihood of smoking cessation in the NRT 
groups compared to the placebo groups (OR = 1.55; 
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95% CI: 1.49–1.61) [23]. The effects were significant for 
all types of NRT: for users of nicotine gums, the odds 
ratio was 1.64, for users of nicotine patches — 1.52 and 
for users of nicotine inhalers — 1.90 [73].
Antidepressants can help in the fight against the ad-
diction to smoking for several reasons. Withdrawal from 
nicotine can cause depressive symptoms, and antidepres-
sants can relieve them. In addition, some antidepressants 
may have specific effects on the receptors and messenger 
pathways underlying nicotine addiction. Bupropion is 
an antidepressant that inhibits the postsynaptic uptake 
of dopamine and norepinephrine, reducing the feel-
ing of pleasure from nicotine. Bupropion also blocks 
nAChR, alleviates withdrawal symptoms, including the 
urge to smoke, and reduces weight gain after giving up 
nicotine use [72].
Smokers should start using the drug one week before 
the planned smoking cessation date with an initial dose 
of 150 mg a day for 3 days, and then 150 mg twice a day 
for 6 to 12 weeks. A smoker can suddenly stop taking 
the drug without having to gradually reduce the dose. 
The most reported side effects of bupropion include in-
somnia, dry mouth, nausea, and skin allergic reactions [72].
Based on a meta-analysis of 45 randomized trials 
(17,866 participants) from a Cochrane systematic review 
that assessed the frequency of giving up smoking in 
a long-term follow-up with bupropion versus placebo, 
the drug effectiveness was demonstrated (OR = 1.64, 
95% CI: 1.52–1.77) [25]. In comparison to the placebo 
group, smokers treated with bupropion more often 
resigned from participation in the study due to adverse 
events (OR = 1.37, 95% CI: 1.21–1.56; 25 studies, 
12,340 participants). Those in the bupropion group were 
also more likely to report psychiatric adverse effects 
compared to those in the placebo group (OR = 1.25, 
95% CI: 1.15–1.37; 6 studies, 4,439 participants). 
The meta-analysis did not provide sufficient evidence 
for the greater effectiveness of the combination therapy 
with bupropion and NRT compared to NRT alone 
(OR = 1.19, 95% CI: 0.94–1.51; 12 studies, 3,487 par-
ticipants) or the advantage of combining bupropion and 
varenicline compared to varenicline alone (OR = 1.21, 
95% CI: 0.95–1.55; 3 studies, 1,057 participants). A me-
ta-analysis of 6 studies provided evidence that bupropion 
was less effective than varenicline (OR = 0.71, 95% CI: 
0.64–0.79; 6 studies, 6,286 participants). In contrast, the 
likelihood of giving up smoking when using bupropion 
was similar to that with NRT (OR = 0.99, 95% CI: 
0.91–1.09; 10 studies, 8,230 participants) [74].
Varenicline is a partial a4b2 nAChR antagonist. 
It shows a strong antagonistic effect against nicotine. It is 
a partial competition agonist of nAChR, which reduces 
their availability for nicotine, decreasing the satisfaction 
with smoking and the feeling of reward after smoking 
a cigarette. Varenicline, although it is less agonist than 
nicotine on nAChR, leads to a reduction in the feeling 
of craving and withdrawal symptoms in people who give 
up smoking [72].
The 12-week treatment should be started 2 weeks 
before the planned smoking cessation date. In the initial 
phase, 1 tablet of 0.5 mg should be taken once a day for 
3 days, for the next 4 days 2 × 1 tablet of 0.5 mg, and 
for the next week 2 × 1 tablet of 1 mg. In the treatment 
continuation phase after giving up smoking, it is recom-
mended to take 1 tablet twice a day. If the attempt to 
give up smoking is unsuccessful, treatment continues, 
and the patient tries to stop smoking on the next day 
until successful. The most common side effects of vareni-
cline include nausea, usually of moderate intensity, and 
intense dreaming with restlessness, insomnia, head-
ache, arrhythmias, and mood changes. Cautious use of 
varenicline is recommended in patients with depressed 
mood, although a meta-analysis of 10 randomized, pla-
cebo-controlled studies on the effectiveness and safety 
of varenicline when giving up smoking showed similar 
rates of new symptoms and mental illness in the placebo 
(9.7%) and varenicline groups (10.7%) (OR = 1.02, 95% 
CI: 0.86–1.22) [74].
Based on a meta-analysis of 27 randomized trials 
(12,625 participants) included in the Cochrane sys-
tematic review, it was indicated that treatment with 
standard-dose varenicline more than doubled the chance 
of long-term smoking cessation compared to placebo 
(OR = 2.24, 95% CI: 2.06–2.43). A meta-analysis of 
5 studies (5,877 participants) comparing the effectiveness 
of varenicline and bupropion, and a meta-analysis of 
8 studies (6,264 participants) comparing the effectiveness 
of varenicline and NRT showed the superiority of vareni-
cline in long-term smoking cessation (OR = 1.39, 95% CI: 
1.25–1.54 and OR = 1.25, 95% CI: 1.14–1.37) [75].
Cytisine is a quinolizidine alkaloid extracted from 
the seeds of the golden chain (Laburnum anagyroides). 
It is a competitive, partial agonist of a4b2 nAChR, and 
its mechanism of action is similar to varenicline. For 
several decades, cytisine has been available in Poland 
as an oral drug in the treatment of nicotine addiction 
[72]. Cytisine treatment should be started up to 5 days 
before the planned smoking cessation date. For the 
first 3 days, 1 tablet of 1.5 mg is used 6 times a day, for 
the next 9 days 1 tablet 5 times a day, from the 13th to 
the 16th day 1 tablet 4 times a day, from the 17th to the 
20th day 1 tablet 3 times a day and from the 20th to the 
25th day 1 tablet once or twice a day. The most common 
side effects during treatment include nausea, vomiting, 
diarrhoea, tachycardia, and an increase in blood pres-
sure [76, 77].
A systematic review published in the Cochrane Li-
brary includes 3 studies on the effectiveness of cytisine 
in the treatment of smoking addiction. In two studies 
(937 participants) it was found that patients treated 
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with cytisine were four times more likely not to smoke 
after 6 months of follow-up in comparison to placebo 
(OR = 3.98, 95% CI: 2.01–7.87). One study compared 
the effectiveness of cytisine with NRT (1,310 subjects) 
and showed the advantage of cytisine six months after the 
start of treatment (OR = 1.43, 95% CI: 1.13–1.80) [75].
The use of e-cigarettes or heat-not-burn devices in 
the fight against smoking addiction is still debatable. 
All scientific societies dealing with this issue and agen-
cies assessing medical technologies, such as the National 
Institute for Health and Care Excellence (NICE) or 
the FDA, emphasize that there are no completely safe 
products containing tobacco, and the most effective 
method of reducing health risk in tobacco smokers is 
to give up smoking completely. Both agencies state, 
however, that in people who are highly addicted to 
nicotine and who smoke cigarettes, reduction of health 
risk is possible thanks to the temporary or long-term 
use of licensed nicotine-containing products instead of 
traditional cigarettes [63–65].
Based on a toxicological analysis by the Committee 
on Toxicity [38], the NICE concluded that licensed 
nicotine products, approved by the MHRA, contain 
significantly less harmful substances compared to tra-
ditional cigarettes and under certain conditions can be 
used as an aid in reducing addiction to tobacco smoking 
if smokers decide to switch completely to smokeless 
products containing nicotine. However, the NICE 
made a reservation that strict control over the use of 
these products, the composition of an aerosol and the 
prohibition of access to them for children and adoles-
cents, as well as further clinical and scientific research 
on their safety are required (e.g., NCT03569748 study 
aimed at comparing the safety and effectiveness of us-
ing e-cigarettes and HnB products in reducing tobacco 
addiction is in the process) [63, 78].
The use of e-cigarettes to reduce tobacco addic-
tion is most controversial. As mentioned above, the 
e-cigarette market is not sufficiently controlled, resulting 
in the appearance of contaminated products, including 
THC-containing products, on the market-leading to seri-
ous and life-threatening pulmonary toxicity. Moreover, 
e-cigarettes are a fashionable and attractive product ea-
gerly bought by children and adolescents, which leads to 
nicotine addiction and more frequent use of traditional 
cigarettes by people in this age group [46]. The results 
of a study conducted in 2020 by the National Institute 
of Public Health - National Institute of Hygiene showed 
that the products initiating nicotine consumption were 
traditional cigarettes for 52% of teenagers, electronic 
cigarettes for 32%, and HnB products for 0.2% [79]. 
Similar results were obtained in a study commissioned 
by the European Commission (Eurobarometer 2021), 
according to which in 87% of cases, traditional cigarettes 
and roll-your-own tobacco are responsible for the ini-
tiation of nicotine use. The remaining products played 
a much smaller role in the initiation of addiction (water 
pipes with tobacco — 4%, e-cigarettes — 2%, snus and 
HnB products < 1%) [80].
The FDA has issued an opinion on the use of to-
bacco heat-not-burn devices (but not e-cigarettes) as 
a way to reduce health risks in smokers, granting HnB 
products an MRTP status. The FDA opinion was based 
on 30 analyses and reports, the results of 10 clinical 
studies, 8 non-clinical studies, 141 independent scientific 
studies and 340 peer-reviewed articles. They have shown 
that a complete transition from traditional cigarettes to 
a tobacco heat-not-burn system significantly reduces 
exposure to harmful or potentially harmful substances, 
which can help addicted adult smokers give up smok-
ing and reduce their exposure to harmful factors. 
In addition, the FDA has made a reservation that it 
will closely monitor how tobacco heating systems are 
used by consumers and whether they do not adversely 
affect their health and that the use of these products by 
adolescents is not increasing, which would lead this age 
group to nicotine addiction. It was emphasized that HnB 
products are not completely safe and people, especially 
young people who do not currently use tobacco products, 
cannot start using them [64, 65]. Similar recommenda-
tions were also issued by the Dutch National Institute 
of Public Health and the Environment (RIVM), 
the Belgian High Council for Health, the German 
Federal Institute for Risk Assessment (German Bun-
desinstitut für Risikobewertung, BfR) and the Japanese 
National Institute of Public Health [61–63, 79, 81].
In Poland, there are no such recommendations is-
sued by state organizations. There are, however, expert 
opinions. One of them is the opinion of Szymański et 
al. [82], in which the authors state that HnB products 
may potentially be helpful in the treatment of tobacco 
addiction and in reducing the adverse health effects as-
sociated with this addiction. They also state that HnB 
products may be a safer alternative to cigarettes in 
people in whom all, including pharmacological, treat-
ments for tobacco dependence have failed [82]. Polish 
guidelines for the management of lower limb artery dis-
ease by Jawień et al. [83] also emphasize that replacing 
traditional cigarettes with heat-not-burn products may 
be an alternative in the treatment of smoking addiction.
Summary
Lung cancer risk factors are largely known and well 
characterized. Therefore, primary prevention of this 
disease seems to be easy to implement by eliminat-
ing environmental threats and smoking. Neverthe-
less, lung cancer remains the leading cause of deaths 
among malignant cancers in all developed countries. 
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The reasons for this phenomenon should be sought for 
in the growing problem of environmental pollution, 
but above all in the difficulties in eliminating the ad-
diction to smoking in the Polish population. Due to the 
lack of adequate education, young people still turn to 
nicotine-containing products, first e-cigarettes and then 
traditional cigarettes. On the other hand, nicotine addic-
tion is extremely strong in many people and its elimina-
tion using traditional methods (psychotherapy, nicotine 
replacement therapy, pharmacotherapy) turns out to be 
impossible. In these people, reducing the health risks 
associated with smoking can be achieved by replacing 
cigarettes with smokeless nicotine-containing prod-
ucts. Many scientific studies have shown that aerosols 
from e-cigarettes and heat-not-burn devices contain over 
90% fewer carcinogens than cigarette smoke. However, 
it should be remembered that while the composition of 
aerosols in heat-not-burn devices is known, in the case 
of e-liquids it may be modified by e-cigarette owners or 
companies producing them (this was the cause of many 
cases of acute lung damage in people using e-liquids 
containing THC and vitamin E acetate). Therefore, 
many countries (the USA, the Netherlands, Belgium, 
Germany) have identified HnB devices as products with 
a reduced health risk compared to traditional cigarettes, 
and experts from many countries issue cautious recom-
mendations on the possibility of reducing the health 
risk in people smoking cigarettes by replacing them with 
heat-not-burn products.
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